Health & Medical Archives | Be Korea-savvy

Archive by category Health & Medical

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B

NEW YORK and CLEVELAND, Jan. 19 (Korea Bizwire) — Abeona Therapeutics Inc. (Nasdaq:ABEO), a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/226/16) for Abeona’s gene therapy program ABO-101 for children impacted by [...]

RedHill Biopharma Provides 2017 Semi-Annual Business Update

RedHill Biopharma Provides 2017 Semi-Annual Business Update

TEL-AVIV, Israel, Jan. 12 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today provided an update on key programs, potential milestones and estimated timelines. Micha [...]

RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections

RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections

TEL-AVIV, Israel, Jan. 11 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation [...]

RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection

RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection

TEL-AVIV, Israel, Jan. 10 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced first dosing in a three-way crossover pharmacokinetic (PK) study with RHB-105 [...]

Bioline Launches the Full Range of EPIK™ miRNA Assays

Bioline Launches the Full Range of EPIK™ miRNA Assays

CINCINNATI, Jan. 9 (Korea Bizwire) — Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the EPIK™ miRNA Select Assays, originally developed for the study of individual microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800 EPIK™ miRNA Select Assays in March 2016 and this has [...]

RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management

RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management

TEL-AVIV, Israel, Jan. 9 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the exercise, in the last week, of stock options to purchase [...]

RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference

RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference

TEL-AVIV, Israel, Jan. 6 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the presentation of an abstract relating to YELIVA®, the Company’s proprietary, [...]

RedHill Biopharma Announces Exercise of Underwriters’ Option

RedHill Biopharma Announces Exercise of Underwriters’ Option

TEL-AVIV, Israel, Jan. 3 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the underwriters of its previously announced underwritten public offering of [...]

RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal®

RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal®

TEL-AVIV, Israel, Jan. 3 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the signing of an exclusive co-promotion agreement with a subsidiary2 of Concordia [...]

RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters

RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters

TEL-AVIV, Israel, Dec. 27 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering and its concurrent [...]